IPG1094 Phase I Study for China Healthy Participants

计划入组 24 人 · 首次发布于 2026 年 7 月 1 日

AdvisaTM IPG Clinical Evaluation Study

计划入组 79 人 · 首次发布于 2009 年 2 月 9 日

IPG Replacement Study (PREFERENCE-H)

计划入组 17 人 · 首次发布于 2016 年 11 月 15 日

IPG

IPG-1094

IPG-8294

IPG Pharmaceuticals, Inc.

United States

Axcella Health

United States

Astrana Health

United States

New White Paper Highlights Critical Success Factors for Modern Pharmaceutical Product Launches

Experts to Explore Cell and Gene Therapy Frontiers in Rare Disease Treatment at Upcoming Webinar

Nalu Reports 94% Response Rate in Largest Real-World Study of Peripheral Nerve Stimulation Device